Brokerages Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $15.50

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have earned an average rating of “Moderate Buy” from the five research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $15.50.

Several equities analysts recently weighed in on the stock. HC Wainwright raised shares of Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 price objective on the stock in a research report on Wednesday, November 5th. Canaccord Genuity Group increased their price target on shares of Ventyx Biosciences from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Wells Fargo & Company raised their price target on shares of Ventyx Biosciences from $11.00 to $14.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Wall Street Zen raised shares of Ventyx Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Ventyx Biosciences in a research report on Wednesday, October 8th.

Ventyx Biosciences Trading Up 2.0%

Shares of NASDAQ:VTYX opened at $8.00 on Tuesday. The firm has a market cap of $570.88 million, a price-to-earnings ratio of -5.33 and a beta of 1.22. Ventyx Biosciences has a 1 year low of $0.78 and a 1 year high of $10.55. The business has a fifty day simple moving average of $6.83 and a 200 day simple moving average of $3.98.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.13. On average, sell-side analysts forecast that Ventyx Biosciences will post -2.09 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VTYX. Ashton Thomas Private Wealth LLC acquired a new stake in Ventyx Biosciences during the second quarter worth about $71,000. Nuveen LLC bought a new stake in shares of Ventyx Biosciences in the 1st quarter worth approximately $194,000. Ieq Capital LLC acquired a new stake in shares of Ventyx Biosciences during the 1st quarter worth approximately $223,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Ventyx Biosciences by 8.4% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 945,206 shares of the company’s stock worth $2,023,000 after purchasing an additional 73,601 shares in the last quarter. Finally, Pallas Capital Advisors LLC bought a new stake in shares of Ventyx Biosciences during the second quarter valued at approximately $38,000. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.